Merck Animal Health’s Bravecto Receives the US FDA’s Approval to Treat Asian Long-Horned Ticks in Dogs
- The company has expanded the indication for Bravecto Chews to include the treatment & control of Asian long-horned ticks in dogs
- Through the US FDA approval, Merck has been able to extend its Bravecto product portfolio to provide a broad-spectrum comprehensive line of parasite protection products delivering immediate & persistent killing activity in dogs
- Bravecto (112.5, 250, 500, 1000 & 1400 mg fluralaner/chew) is a chewable tablet indicated for the treatment & prevention of flea infestations, treatment & control of Amblyomma americanum infestations (for 8wks.), tick infestations, Dermacentor variabilis, Rhipicephalus sanguineus & Haemaphysalis longicornis (for 12wks.)
Ref: Businesswire | Image: Merck
Related News:- Merck Animal Health Signed a Definitive Agreement to Acquire Vence
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].